Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractor

# # #
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of cilta-cel. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC?or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned ?Cautionary Note Regarding Forward-Looking Statements? and ?Item 1A. Risk Factors,? and in the company?s most recently filed Quarterly Report on Form 10-Q, and the company?s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at?www.sec.gov,?www.jnj.com?or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. Media Contacts: Brian Kenney Phone: +1 215-620-0111 Satu Glawe Phone: +49 172-294-6264 Investor Relations: Jennifer McIntyre Office: +1 732-524-3922 U.S. Medical Inquiries: +1 800-526-7736December
[1]?Tai YT, et al. Targeting B-cell maturation antigen in multiple myeloma.?https://www.ncbi.nlm.nih.gov/pubmed/26370838. Accessed December 2020.
[2]?Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.
[3]?American Cancer Society. "What Is Multiple Myeloma?" Available at:?http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed December 2020.
[4]?American Cancer Society. "Key Statistics About Multiple Myeloma." Available at:?https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed December 2020.